Author’s response to reviews

Title: Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications

Authors:

Sarah Kelddal (sarah.kelddal@midt.rm.dk)
Karen Nykjær (karen.marie.nykjaer@vest.rm.dk)
Jon Gregersen (jonwgregersen@gmail.com)
Henrik Birn (hb@biomed.au.dk)

Version: 2 Date: 12 Apr 2019

Author’s response to reviews:

Dear Jing Zhang

Attached please find the revised version of our manuscript entitled “Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications”, ID BNEP-D-19-00036, which we hope you will reconsider for publication in BMC Nephrology. We thank for the reviewers thoughtful comments, and the manuscript has been revised accordingly.

The following outline our point-to-point response to the comments. Additionally, every change in the manuscript is trackable in the resubmitted manuscript.

On behalf of the authors

Yours sincerely,

Sarah Kelddal
Responds to Editor Comments to author:

Comment 1.
The INR of the 2 patients with major bleeding has not been mentioned in the author response
(Reviewer 1: “What was the INR of the 2 patients who had major bleeding? Please report the average INR of entire cohort”)

Response:
Unfortunately, INR was not recorded at the onset of the bleeding episodes.
This has now been clearly stated in the Discussion section (Line 163-164)

Comment 2.
Please include the following statement in the manuscript
"Aspirin was not used as PAC, but patients treated with aspirin prior to the diagnosis of NS continued the treatment when initiated on LMWH and/or warfarin. Aspirin was in general prescribed to prevent cardiovascular disease; however, the exact indication in these 11 patients was not recorded."

Response:
This has now been included in the Methods section (Line 89-92)
Other revisions:

1. Published Abstract:
   • The abstract has rephrased to minimize overlap with previous congress submissions.

2. Section Headings
   • “Introduction” is renamed “Background” (Line 38)
   • “Materials and Methods” is renamed “Methods” (Line 68)

3. Authors’ contributions
   • The authors’ names are replaced by full initials (Line 233-236)

4. Declarations
   • We inserted a Declarations section and have reviewed and revised this section to ensure that everything relevant is included within the required subsections (lines 216 to 243).

5. Figure legends
   • Legend to Figure 1 has been placed as text following the reference section (Line 292)